Neumora Therapeutics is trading 8.37% higher at $0.40 in pre-market; the reason for the move remains unclear. - Shares closed October 13 at $0.37 after falling 15.34% in that session. - Available reports identify no clear overnight company-specific catalyst. Latest coverage notes a Wall Street Zen downgrade to Strong Sell but does not connect it to the pre-market rise. - Latest surfaced announcements are earlier pipeline updates, not news dated October 14. Broader index futures are only modestly higher, and available evidence does not establish a market-wide explanation.